Navigation Links
Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
Date:1/25/2012

NEW YORK, Jan. 25, 2012 /PRNewswire/ -- Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: NBS)("NeoStem" or the "Company") today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous bone marrow derived cell therapy enriched for CD34+ cells. AMR-001 is administered 5 to 11 days post-stent placement in patients diagnosed with an ST segment elevation myocardial infarction with ejection fraction less than or equal to 48%, as determined by cardiac magnetic resonance imaging measured after recovery from myocardial stunning.  Approximately 160 subjects, age 18 and older, will be randomized 1:1 between the treatment group and control group.  Progenitor Cell Therapy, LLC, also a NeoStem company, will support the manufacturing, product supply, and logistics for the trial.

Dr. Arshed Quyyumi, Professor of Medicine at Emory University and the lead principal investigator in the study said, "We are thrilled to begin evaluating AMR-001, a CD34+ cell therapy, in these patients. We look forward to Phase 2 trial confirmation of the biologic activity of AMR-001 demonstrated in the Phase 1 trial and hope to provide patients with significant clinical benefit and an enriched quality of life."

"The first patient enrollment signals a key advance in our efforts in the trial," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. "We are on track to enroll the targeted 160 patients over the next year or so with first data follow-up six months after the last patient is enrolled."

AMR-001 represents the first compound in this class of cell therapies to have a highly defined cell population and an identified biologically effective therapeutic dose, both of which tie back to the
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
2. NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations
3. NeoStem Announces Change in Presentation Time for JMP Securities Conference
4. NeoStem Announces Participation in Multiple September Conferences
5. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
6. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
7. NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
8. NeoStem Announces Proposed Public Offering of Common Stock
9. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
10. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
11. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Noser Health and Netcetera ... deliver new platform   ... data transaction platform, announced today strategic partnerships with ... and bring to market its global health data transaction ... "Our business model is built on trust, neutrality, impact ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., ... of cancer, today announced the filing of a registration ... Exchange Commission (SEC) relating to a proposed initial public ... to be offered and the price range for the ... list its common stock under the symbol "CTMX" on ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... their peers may be at a greater risk for injury, potentially because they ... a University of Pittsburgh Graduate School of Public Health analysis discovered. , ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... On Saturday, ... A Mission” at the Adams County Fairgrounds in Mendon, IL. The purpose behind this ... districts of Mendon and neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband use oxygen therapy ... Ky. “I thought there could be a comfortable way to prevent the irritation, so ... Ear Protector offers a more secure way to anchor the cannula tubing used in ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... medical professional association for physicians and allied health professionals dedicated to using ... Foundation, announced today the establishment of the Lifestyle Medicine Lifetime Achievement and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... by drug researchers has revealed that enabling controlled doses of ... //would serve a dual purpose – of bringing down the ... for a year will come down drastically. , ,National ... perhaps the first ever cost-benefit study of a prison methadone ...
... to information by the Canadian government a confirmed case of ... found. // ,The case was of a 6-year-old ... through a national surveillance program for mad-cow disease. ,In ... of Canadian beef. Tissues in which BSE is known to ...
... According to a Johns Hopkins University behavioral neuroscientist evidence is ... neurotransmitter when acting in the brain. // The study was ... the same direction is an article by Gregory Ball, professor ... university's Krieger School of Arts and Sciences, to be published ...
... rescue group has raised concerns over swans and other wild birds ... //. Despite pleas from wildlife rescue groups, Canada geese, peregrine falcons ... attempts of Salisbury Wildlife Rescue workers to save a swan (found ... up in vain. The bird had to be eventually destroyed by ...
... lack of sleep in children, could lead to obesity. ... faculty of medicine studied 422 grade school students aged ... waist size of each participant. ,They also ... through phone interviews with their parents, reported health portal ...
... the country focuses on headline-grabbing diseases, hemophilia, a little known ... with over 50,000 people affected. // ,World ... global effort to secure appropriate care and treatment for a ... by a defect in the genes. ,"The disease ...
Cached Medicine News:Health News:Cost-Benefit Economics of Methadone for prisoners 2
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
... Topical, Bactericide, Microbicide for professional ... technology in skin disinfectants combining quaternary ... a synergistic blend of emollients and ... and gram-positive organisms tested in 30 ...
... bonds with the skin ... germ-killing field. In addition ... antimicrobial effect, HIBICLENS' non-drying, ... promotes compliance with the ...
... solution, allows the user to prep one ... in less than 2-minutes. It also utilizes ... surgical scrubbing and healthcare personnel handwashing. ACTIPREP ... provide a tacky surface for drapes to ...
Medicine Products: